Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why
TG Therapeutics Inc's (NASDAQ:TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) HC Wainwright has slashed the price target from $68 to $19, with the Buy rating unchanged.…
Benzinga ·